Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial
Authors:
- Manju L. SubramanianManju L. Subramanian
- Steven NessSNSteven Ness
- Gelareh AbediGAGelareh Abedi
- Ednan AhmedEAEdnan Ahmed
- Mary DalyMDMary Daly
- Edward FeinbergEFEdward Feinberg
- Sumit BhatiaSBSumit Bhatia
- Payal PatelPPPayal Patel
- Maileah NguyenMNMaileah Nguyen
- Antoun HouraniehAHAntoun Houranieh
- 1 December 2009
- journal article
- research article
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 148 (6) , 875-882.e1
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Vascular endothelial growth factor in eye diseaseProgress in Retinal and Eye Research, 2008
- Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 casesBritish Journal of Ophthalmology, 2007
- Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month resultsEye, 2007
- Vascular endothelial growth factor: Biology and therapeutic applicationsThe International Journal of Biochemistry & Cell Biology, 2007
- Verteporfin Therapy and Intravitreal Bevacizumab Combined and Alone in Choroidal Neovascularization due to Age-Related Macular DegenerationOphthalmology, 2007
- The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBritish Journal of Ophthalmology, 2006
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular DegenerationNew England Journal of Medicine, 2006
- Intravitreal Avastin: The Low Cost Alternative to Lucentis?American Journal of Ophthalmology, 2006